Indication
Cutaneous T-cell Lymphoma
13 clinical trials
18 products
Clinical trial
A Phase 1 Clinical Trial to Study the Safety, Pharmacokinetics, and Efficacy of BP1002 (L-Bcl-2) Antisense Oligonucleotide in Patients With Advanced Lymphoid MalignanciesStatus: Recruiting, Estimated PCD: 2024-09-01
Product
L-Bcl-2Clinical trial
An Exploratory Clinical Study to Investigate the Effect of autoSTEM-OA and alloSTEM-OA in Participants With Knee Osteoarthritis.Status: Not yet recruiting, Estimated PCD: 2024-11-01
Product
FenretinideClinical trial
A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell LymphomaStatus: Recruiting, Estimated PCD: 2024-06-01
Product
SIM1811-03Clinical trial
A Phase I/Ib, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination With Capecitabine, Given Orally on a Daily Schedule in Patients With Advanced Solid Tumors or LymphomaStatus: Active (not recruiting), Estimated PCD: 2023-05-01
Product
GZ17-6.02Product
CapecitabineClinical trial
A Phase II Study of L19IL2/L19TNF in Patients With Skin Cancers Amenable to Intralesional TreatmentStatus: Recruiting, Estimated PCD: 2024-06-01
Product
L19IL2/L19TNFClinical trial
Multi-center, Phase 2, Open-label Study of Efficacy and Safety of the Selective Inhibitor of Nuclear Export (SINE™) Selinexor (KPT-330) in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) and Cutaneous T-cell Lymphoma (CTCL)Status: Terminated, Estimated PCD: 2016-01-01
Product
SelinexorClinical trial
Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.Status: Not yet recruiting, Estimated PCD: 2024-12-01
Product
TriamcinoloneProduct
BexaroteneProduct
Nitrogen MustardClinical trial
A Phase Ib Trial Combining Bexarotene With Ultra-Low Dose Total Skin Electron Beam (Tseb) Radiotherapy For The Treatment Of Diffuse Cutaneous T-Cell LymphomasStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase I Trial Assessing the Feasibility of Romidepsin Combined With Brentuximab Vedotin for Patients Requiring Systemic Therapy for Cutaneous T-cell LymphomaStatus: Active (not recruiting), Estimated PCD: 2023-02-20
Product
RomidepsinProduct
Brentuximab vedotinClinical trial
Phase I/II Study of Linperlisib in Combination With Chidamide for Relapsed and Refractory Cutaneous T-cell Lymphoma: a Prospective, Single-center StudyStatus: Recruiting, Estimated PCD: 2024-07-01
Product
LinperlisibClinical trial
Open-Label Extension Study of Anti-CCR4 Monoclonal Antibody KW-0761 as Monotherapy in Subjects Who Relapsed After Complete Response on Study KW-0761-001Status: Completed, Estimated PCD: 2012-09-01
Product
KW-0761Clinical trial
A Phase II Study of Non-myeloablative Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) In Patients With Cutaneous T Cell LymphomaStatus: Completed, Estimated PCD: 2021-11-06
Product
Anti-thymocyte globulinProduct
cyclosporineClinical trial
An Open-Label, Multicenter Phase IIa Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Puesta Mesylate for Injection for the Treatment of Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell LymphomaStatus: Recruiting, Estimated PCD: 2025-11-22
Product
Purinostat Mesylate